Soterix grabs patent for transcranial stimulation in fibromyalgia
This article was originally published in Clinica
Executive Summary
Soterix Medical has been granted a US patent for its high-definition transcranial direct current stimulation (HD-tDCS) platform, which is being trialed in a Phase II study for fibromyalgia. The disorder, a type of chronic pain that disproportionately affects women, can occur with other problems including depression, anxiety and irritable bowel syndrome.